Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8361517 | 0.90 | TDP1 (0.58) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL14388905 | 0.89 | TDP1 (0.46) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL9077656 | 0.89 | FBP1 (0.50) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL14388907 | 0.87 | TDP1 (0.47) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL18816139 | 0.87 | TSHR (0.59) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL18816130 | 0.87 | TDP1 (0.47) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL9077669 | 0.86 | TDP1 (0.43) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL8730292 | 0.86 | TDP1 (0.43) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL8172704 | 0.84 | FBP1 (0.49) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 | |
| SCHEMBL18184974 | 0.84 | TDP1 (0.48) | TDP1TSHRALDH1A1FBP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815768-B2 | Method for producing 2-(halogenomethyl)-3-methylnitrobenzene | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20160332956-A1 | METHOD FOR PRODUCING 2-(HALOGENOMETHYL)-3-METHYLNITROBENZENE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-11-17 | — | — | US | disclosed |
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1053990-A2 | A method of producing an aromatic ketone and an aromatic ketone composition containing it | TORAY INDUSTRIES, INC. (JP) | 2000-11-22 | — | — | EP | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0732942-A4 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | COCENSYS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| US-4502995-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1985-03-05 | — | — | US | disclosed |
| US-4171425-A | ANIONIC CATALYST, 2-PYRROLIDONE OR E-CAPROLACTAM | CHEVRON RESEARCH COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
| US-4051187-A | CARBON CATALYST WITH SYNERGISTIC QUANTITIES OF THODIUM, TRICHLORIDE OR RHODIUM TRIBROMIDE | OXAMINE, INC. (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332956-A1 | METHOD FOR PRODUCING 2-(HALOGENOMETHYL)-3-METHYLNITROBENZENE | CYP1B1, DNMT1, DNMT3A | TDP1 2652/4885TSHR 1157/4885ALDH1A1 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.